XML 36 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
SHAREHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2016
Stockholders' Equity Note [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 12:-
  SHAREHOLDERS' EQUITY

The ordinary shares of the Company are traded on Nasdaq Global Market and on the Tel Aviv Stock Exchange, under the symbol "CRNT".

a.
General:

The ordinary shares entitle their holders to receive notice to participate and vote in general meetings of the Company, the right to share in distributions upon liquidation of the Company, and to receive dividends, if declared.

b.
In August 2014, the Company completed a public offering of its shares on NASDAQ. The Company issued 21,250,000 of its ordinary shares, nominal value NIS 0.01 per share at a price of $ 1.89 per share before issuance expenses. The Company also granted to the underwriters the option to purchase up to 2,850,000 additional ordinary shares within 30 days, which was fully exercised. Total net proceeds from the issuance amounted to approximately $ 45,149, net of issuance expenses in the amount of $ 400.

c.
Stock options plans:

1.
In 2003, the Company adopted a share option plan (the "Plan"). Under the Plan, options and RSU’s may be granted to officers, directors, employees and consultants of the Company or its subsidiaries. The options vest primarily over four years. The options expire ten years from the date of grant. In December 2012, the Company extended the term of the Plan for an additional period of ten years.

Upon adoption of the Plan, the Company reserved for issuance 8,639,000 ordinary shares in accordance with the respective terms thereof. Any options or RSU’s, which are canceled or forfeited before the expiration date, become available for future grants. As of December 31, 2016, the Company has 779,327 Ordinary shares available for future grant under the Plan.

2.
On September 6, 2010, the Company's board of directors amended the Plan so as to enable to grant Restricted Share Units ("RSUs") pursuant to such Plan.

3.
The following is a summary of the Company's stock options and RSUs granted among the various plans:

   
Year ended
December 31, 2016
  
   
Number
of options
    
Weighted
average
exercise
price
    
Weighted average remaining contractual term
(in years)
    
Aggregate
intrinsic
value
  
                         
Outstanding at beginning of year
    
6,465,782
    
$
4.81
      
4.76
    
$
88
  
Granted
    
1,777,875
    
$
1.43
                  
Exercised
    
(72,832
)
  
$
1.18
                  
Forfeited or expired
    
(680,652
)
  
$
6.78
                  
                                 
Outstanding at end of the year
    
7,490,173
    
$
3.86
      
4.33
    
$
6,003
  
                                 
Options exercisable at end of the year
    
4,021,641
    
$
6.01
      
3.92
    
$
1,639
  
                                 
Vested and expected to vest
    
6,611,066
    
$
4.20
      
4.26
    
$
4,842
  

   
Year ended
December 31, 2016  
  
   
Number
of RSUs
    
Aggregate
intrinsic
value
  
             
Outstanding at beginning of year
    
106,768
    
$
120
  
Granted
    
-
          
Exercised
    
(59,233
)
        
Forfeited
    
-
          
                 
Outstanding at end of the year
    
47,535
    
$
125
  
                 
Vested and expected to vest
    
43,118
    
$
113
  
 
The Company's options are generally granted at exercise prices which are equal to the average market value of the ordinary shares in the period of 30 trading days prior to the grant date. The weighted average grant date fair value of the options granted during 2014, 2015 and 2016 were $ 0.96, $ 0.54 and $ 0.78, respectively. No RSUs were granted during 2015 and 2016.
 
The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on the last trading day of the year and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of the year.

This amount is impacted by the changes in the fair market value of the Company's shares. Total intrinsic value of options and RSUs exercised during the years ended December 31, 2015 and 2016 were $ 480 and $ 238, respectively. As of December 31, 2016, there was $ 1,085 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a weighted-average period of 0.92 years.
 
The following is a summary of the Company's stock options and RSUs granted separated into ranges of exercise price:

Exercise price
(range)
    
Options and RSUs outstanding
as of
December 31, 2016
    
Weighted
average
remaining
contractual
life (years)
    
Weighted
average
exercise
price
    
Options and RSUs exercisable
as of
December 31, 2016
    
Remaining contractual life (years for exercisable options
    
Weighted
average
exercise
price
  
$
                
$
                
$
  
                                       
RSUs 0.0
      
47,535
            
0.00
      
-
              
0.01-2.00
      
4,015,854
      
4.65
      
1.19
      
1,064,599
      
4.36
      
1.19
  
2.01-4.00
      
921,522
      
4.72
      
2.49
      
420,067
      
4.37
      
2.62
  
4.01-6.00
      
933,139
      
2.94
      
5.22
      
917,317
      
2.88
      
5.23
  
6.01-8.00
      
41,500
      
5.39
      
6.84
      
41,500
      
5.39
      
6.84
  
8.01-10.00
      
845,074
      
4.17
      
9.07
      
845,074
      
4.17
      
9.07
  
10.01-13.04
      
733,084
      
3.94
      
12.35
      
733,084
      
3.94
      
12.35
  
                                                   
       
7,537,708
                      
4,021,641
                  
 
The total equity-based compensation expense related to all of the Company's equity-based awards, recognized for the years ended December 31, 2014, 2015 and 2016, was comprised as follows:

   
Year ended
December 31,
  
   
2014
    
2015
    
2016
  
                   
Cost of revenues
  
$
215
    
$
73
    
$
30
  
Research and development
    
1,625
      
736
      
151
  
Selling and marketing
    
674
      
495
      
369
  
General and administrative
    
831
      
321
      
521
  
                         
Total stock-based compensation expenses
  
$
3,345
    
$
1,625
    
$
1,071
  

d.
Dividends:

In the event that cash dividends are declared in the future, such dividends will be paid in NIS or in foreign currency subject to any statutory limitations. The Company does not intend to pay cash dividends in the foreseeable future.